TrialJournal of clinical pharmacology2017

Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia.

Yan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.